

Answering Reviewers

Thank you for your comments concerning our manuscript entitled “PRaG 3.0 therapy-a novel combination therapy of RC48, radiotherapy, PD-1 inhibitor, GM-CSF and IL-2 for HER2-positive metastatic pancreatic ductal adenocarcinoma: A case report” (ID:90472). These comments are all valuable and very helpful for revising and improving our manuscript. We have studied comments carefully and have made correction which we hope to meet with approval.

Comments:1. Title. The title does reflect properly the content of the manuscript. The type of article is clearly stipulated: clinical case report.

Answer: Thank you for your comment, this part was not modified.

2. Abstract. The abstract reflects very well all aspects of the manuscript, with clear subchapters. 3. Key Words. Well chosen, but I will suggest removing “case report”, since this type of information is visible within the type of article itself. I would suggest “novel” as a possible replacement.

Answer: Thank you for your comment, we removed “case report” and added “novel combination therapy”.

4. Background. The background is constructed according to a case presentation paper.

Answer: Thank you for your comment, this part was not modified.

5. Methods. This section is constructed according to a case presentation paper. The level of detail is consistent with a case report. Also, the provided CARE Checklist adds more clarity to the paper. 6. Results. This section is constructed according to a case presentation paper. The level of detail is consistent with a case report.

Answer: Thank you for your comment, this part was not modified.

7. Discussion. This section is constructed according to a case presentation paper. The level of detail is consistent with a case report. The number of citations is adequate, and the time span is appropriate. However, please add

the proper citation references for the following statements: - in LINE 202, regarding the success rate of first line AG chemotherapy. - in LINE 212, regarding the characteristics of durvalumab (PD-L1 inhibitor) during the mentioned phase II trial.

Answer: Thank you for your comment, we added the two citation references.

8. Illustrations and tables. All images provided are suitable for publishing.

Answer: Thank you for your comment, this part was not modified.

9. Biostatistics. Not applicable.

Answer: Thank you for your comment.

10. Units. Yes. All medical information have been reported in SI.

Answer: Thank you for your comment.

11. References. The list of references is adequate, also the timespan is appropriate.

Answer: Thank you for your comment

12. Quality of manuscript organization and presentation. It is fit for publication.

Answer: Thank you for your comment

13. Research methods and reporting. The appropriate CARE Checklist (2013) for Case report has been used.

Answer: Thank you for your comment

14. Ethics statements. Documents have been provided.

Answer: Thank you for your comment

15. Backmatter. The informed consent of the patient has been obtained.

Answer: Thank you for your comment

16. Language quality. The English language is consistently good through the entire manuscript. Also, the authors provided a non-native English certificate for professional proofing.

Answer: Thank you for your comment.